These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 37336688)
1. Hepatocyte NLRP3 interacts with PKCε to drive hepatic insulin resistance and steatosis. Qin W; Weng J Sci Bull (Beijing); 2023 Jul; 68(13):1413-1429. PubMed ID: 37336688 [TBL] [Abstract][Full Text] [Related]
2. Hyperhomocysteinemia activates NLRP3 inflammasome to cause hepatic steatosis and insulin resistance via MDM2-mediated ubiquitination of HSF1. Xiang W; Yang Y; Weng L; Ye Z; Ding P; Li H; Sun J; Zeng C Int Immunopharmacol; 2023 May; 118():110085. PubMed ID: 37018978 [TBL] [Abstract][Full Text] [Related]
3. Effects of XIAP on high fat diet-induced hepatic steatosis: a mechanism involving NLRP3 inflammasome and oxidative stress. Zilu S; Qian H; Haibin W; Chenxu G; Deshuai L; Qiang L; Linfeng H; Jun T; Minxuan X Aging (Albany NY); 2019 Dec; 11(24):12177-12201. PubMed ID: 31841118 [TBL] [Abstract][Full Text] [Related]
4. Degradation of PHLPP2 by KCTD17, via a Glucagon-Dependent Pathway, Promotes Hepatic Steatosis. Kim K; Ryu D; Dongiovanni P; Ozcan L; Nayak S; Ueberheide B; Valenti L; Auwerx J; Pajvani UB Gastroenterology; 2017 Dec; 153(6):1568-1580.e10. PubMed ID: 28859855 [TBL] [Abstract][Full Text] [Related]
5. Uric acid regulates hepatic steatosis and insulin resistance through the NLRP3 inflammasome-dependent mechanism. Wan X; Xu C; Lin Y; Lu C; Li D; Sang J; He H; Liu X; Li Y; Yu C J Hepatol; 2016 Apr; 64(4):925-32. PubMed ID: 26639394 [TBL] [Abstract][Full Text] [Related]
6. Dietary saturated fatty acid and polyunsaturated fatty acid oppositely affect hepatic NOD-like receptor protein 3 inflammasome through regulating nuclear factor-kappa B activation. Sui YH; Luo WJ; Xu QY; Hua J World J Gastroenterol; 2016 Feb; 22(8):2533-44. PubMed ID: 26937141 [TBL] [Abstract][Full Text] [Related]
7. Thrombospondin 1 improves hepatic steatosis in diet-induced insulin-resistant mice and is associated with hepatic fat content in humans. Bai J; Xia M; Xue Y; Ma F; Cui A; Sun Y; Han Y; Xu X; Zhang F; Hu Z; Liu Z; Liu Y; Cai G; Su W; Sun X; Wu H; Yan H; Chang X; Hu X; Bian H; Xia P; Gao J; Li Y; Gao X EBioMedicine; 2020 Jul; 57():102849. PubMed ID: 32580141 [TBL] [Abstract][Full Text] [Related]
8. Serum amyloid A1 exacerbates hepatic steatosis via TLR4-mediated NF-κB signaling pathway. Jiang B; Wang D; Hu Y; Li W; Liu F; Zhu X; Li X; Zhang H; Bai H; Yang Q; Yang X; Ben J; Chen Q Mol Metab; 2022 May; 59():101462. PubMed ID: 35247611 [TBL] [Abstract][Full Text] [Related]
9. Asperuloside alleviates lipid accumulation and inflammation in HFD-induced NAFLD via AMPK signaling pathway and NLRP3 inflammasome. Shen Q; Chen Y; Shi J; Pei C; Chen S; Huang S; Li W; Shi X; Liang J; Hou S Eur J Pharmacol; 2023 Mar; 942():175504. PubMed ID: 36641101 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of hepatocyte nuclear factor 1b induces hepatic steatosis through DPP4/NOX1-mediated regulation of superoxide. Long Z; Cao M; Su S; Wu G; Meng F; Wu H; Liu J; Yu W; Atabai K; Wang X Free Radic Biol Med; 2017 Dec; 113():71-83. PubMed ID: 28942246 [TBL] [Abstract][Full Text] [Related]
11. Insulin-like growth factor binding protein 7 accelerates hepatic steatosis and insulin resistance in non-alcoholic fatty liver disease. Yan H; Li T; Wang Y; Li H; Xu J; Lu X Clin Exp Pharmacol Physiol; 2019 Dec; 46(12):1101-1110. PubMed ID: 31397492 [TBL] [Abstract][Full Text] [Related]
12. Hepatic deficiency of selenoprotein S exacerbates hepatic steatosis and insulin resistance. Qiao L; Men L; Yu S; Yao J; Li Y; Wang M; Yu Y; Wang N; Ran L; Wu Y; Du J Cell Death Dis; 2022 Mar; 13(3):275. PubMed ID: 35347118 [TBL] [Abstract][Full Text] [Related]
13. FOXA3 induction under endoplasmic reticulum stress contributes to non-alcoholic fatty liver disease. Liu C; Zhou B; Meng M; Zhao W; Wang D; Yuan Y; Zheng Y; Qiu J; Li Y; Li G; Xiong X; Bian H; Zhang H; Wang H; Ma X; Hu C; Xu L; Lu Y J Hepatol; 2021 Jul; 75(1):150-162. PubMed ID: 33548387 [TBL] [Abstract][Full Text] [Related]
14. Ubiquitin-Specific Peptidase 10 (USP10) Inhibits Hepatic Steatosis, Insulin Resistance, and Inflammation Through Sirt6. Luo P; Qin C; Zhu L; Fang C; Zhang Y; Zhang H; Pei F; Tian S; Zhu XY; Gong J; Mao Q; Xiao C; Su Y; Zheng H; Xu T; Lu J; Zhang J Hepatology; 2018 Nov; 68(5):1786-1803. PubMed ID: 29698567 [TBL] [Abstract][Full Text] [Related]
15. Vitamin D receptor targets hepatocyte nuclear factor 4α and mediates protective effects of vitamin D in nonalcoholic fatty liver disease. Zhang H; Shen Z; Lin Y; Zhang J; Zhang Y; Liu P; Zeng H; Yu M; Chen X; Ning L; Mao X; Cen L; Yu C; Xu C J Biol Chem; 2020 Mar; 295(12):3891-3905. PubMed ID: 32051143 [TBL] [Abstract][Full Text] [Related]
16. Hepatic Krüppel-like factor 16 (KLF16) targets PPARα to improve steatohepatitis and insulin resistance. Sun N; Shen C; Zhang L; Wu X; Yu Y; Yang X; Yang C; Zhong C; Gao Z; Miao W; Yang Z; Gao W; Hu L; Williams K; Liu C; Chang Y; Gao Y Gut; 2021 Nov; 70(11):2183-2195. PubMed ID: 33257471 [TBL] [Abstract][Full Text] [Related]
17. GAS5 protects against nonalcoholic fatty liver disease via miR-28a-5p/MARCH7/NLRP3 axis-mediated pyroptosis. Chen T; Meng Y; Zhou Z; Li H; Wan L; Kang A; Guo W; Ren K; Song X; Chen Y; Zhao W Cell Death Differ; 2023 Jul; 30(7):1829-1848. PubMed ID: 37337032 [TBL] [Abstract][Full Text] [Related]
18. Ubiquitin-Specific Protease 4 Is an Endogenous Negative Regulator of Metabolic Dysfunctions in Nonalcoholic Fatty Liver Disease in Mice. Zhao Y; Wang F; Gao L; Xu L; Tong R; Lin N; Su Y; Yan Y; Gao Y; He J; Kong L; Yuan A; Zhuge Y; Pu J Hepatology; 2018 Sep; 68(3):897-917. PubMed ID: 29573006 [TBL] [Abstract][Full Text] [Related]
19. Targeting DUSP7 signaling alleviates hepatic steatosis, inflammation and oxidative stress in high fat diet (HFD)-fed mice via suppression of TAK1. Wu L; Liu Y; Zhao Y; Li M; Guo L Free Radic Biol Med; 2020 Jun; 153():140-158. PubMed ID: 32311490 [TBL] [Abstract][Full Text] [Related]
20. Hepatic small extracellular vesicles promote microvascular endothelial hyperpermeability during NAFLD via novel-miRNA-7. Zuo R; Ye LF; Huang Y; Song ZQ; Wang L; Zhi H; Zhang MY; Li JY; Zhu L; Xiao WJ; Shang HC; Zhang Y; He RR; Chen Y J Nanobiotechnology; 2021 Nov; 19(1):396. PubMed ID: 34838052 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]